Therapeutic Response

FIP1L1::PDGFRA status confers therapeutic sensitivity to Imatinib in patients with Chronic Eosinophilic Leukemia, NOS.

Statements

Source and description
Gleevec (imatinib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to imatinib for the treatment of adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRa fusion kinase (mutational analysis or fluorescence in situ hybridization [FISH] demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRa fusion kinase negative or unknown.
Glivec (imatinib) [product information]. EMA. The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with a FIP1L1::PDGFRA rearrangement.